Black aspergilli are, the most causes of otomycosis and Aspergillus niger and A. tubingensis are two more frequently isolates. Although, amphotericin B was a gold standard for the treatment of invasive fungal infection for several decades, it replaced by fluconazole and /or voriconazole. Luliconazole, appears to offer the potential for in vitro activity against black aspergilli. The aim of the present study was to compare the in vitro activity of a novel antifungal agent, luliconazole, with commonly used antifungals against clinical and environmental strains of black aspergilli. Sixty seven strains of black aspergilli were identified using morphological and molecular tests (β-Tubulin gene). Aspergillus niger was the common isolate followed by, A. tubingensis and 54.1% (clinical) and 30% (environmental) of isolates were resistant to caspofungin. The highest resistant rate was found in amphotericin B for both clinical (86.5%) and environmental (96.7%) strains. Clinical strains of Aspergillus were more sensitive to voriconazole (86.7%) than environmental strains (70.3%). On the other hand, 83.8% of clinical and 70% of environmental isolates were resistant to posaconazole, respectively. In conclusion, luliconazole compare to routine antifungals is a potent antifungal for A. niger complex in vitro. The MIC range, MIC 50 , MIC 90 and MIC GM of luliconazole against black aspergilli were the lowest among the representative tested antifungals.
Introduction
Luliconazole (Luzu®), (-)-(E)-[(4R)-4-(2,4-dichlorophe-nyl)-1,3-dithiolan-2-ylidene] (1Himidazol-1-yl) acetonitrile), is an imidazole antifungal with molecular formula: C 14 H 9 Cl 2 N 3 S 2 [1] . Luliconazole was basically introduced as anti-dermatophytic antifungal in Japan and India [1, 2] . However, it has demonstrated activity in vitro against multiple Aspergillus spp.
including Aspergillus fumigatus [3, 4] , A. terreus [4, 5] , A. flavus [4, 6] , A. niger [4] and A.
tubingensis [4] . The availability of a novel antifungal, luliconazole, appears to offer the potential for improved therapy for a wide range of invasive fungal infections, including aspergillosis, dermatophytosis, and onychomycosis [2, 7, 8] .
While, amphotericin B was a Gold standard in the first-line treatment of invasive fungal infections for several decades [9] , it has been replaced by several new antifungals including, voriconazole, posaconazole and caspofungin [10, 11] . Voriconazole was presented as the primary therapy for invasive pulmonary aspergillosis in a clinical trials [12] . Further studies have shown that posaconazole is a useful antifungal for invasive fungal infection including aspergillosis [13] . On the other hand, during 2-3 last decades, caspofungin was developed to improve the prognosis of invasive aspergillosis [14] .
The section Nigri (A. niger, sensu lato) contains more than 19 accepted species including, A. niger, A. tubingensis, A. awamory, A. welwitschiae, A. acidus, A. brasiliensis and others [15] [16] [17] [18] . The aspergilli in this section are comprised of several closely related species, and identification based on sequence analyses of β -tubulin gene [4] . Aspergillus niger and A. tubingensis isolates frequently isolated in clinical infections [16, [19] [20] [21] . Black aspergilli cause several types of aspergillosis among predisposed patients [22] [23] [24] [25] . Out of them, otomycosis is the most common cutaneous infection caused by black aspergilli [4, 20] .
The increasing of fungal opportunistic infections among patients receiving intensive chemotherapy, hematological malignancies and transplant patients during last decades is remarkable [10, 23, [26] [27] [28] . Invasive Aspergillus infections are one of the life threatening human disease. On the other hand, some species of Aspergillus have inherent resistance to some antifungal agents [29] . Moreover, some species have raised minimum inhibitory concentration (MIC) against specific antifungals. As a results, infection prevention consultant and the best choice antifungal are common clinical challenges.
Objectives
The aim of the present study was to compare the in vitro activity of a novel antifungal agent, luliconazole, with amphotericin B, voriconazole, posaconazole and caspofungin against clinical and environmental strains of black aspergilli. Furthermore, the potency of each antifungal against clinical and environmental isolates was compared.
Materials and Methods

Fungal isolates
Thirty seven clinical isolates of black aspergilli were previously isolated from otomycosis samples, identified based on morphology characteristics and preserved at Medical Mycology laboratory affiliated to Ahvaz Jundishapur University of Medical Sciences. Environmental strains (30 strains) of black aspergilli were trapped from airborne spores using Sabouraud dextrose agar (SDA) (BioLife, Italia) plates. Primary screening of black aspergilli strains was applied based on macroscopic (Black colony) and microscopic morphology. All strains (clinical and environmental) were subcultured on SDA and re-identified using molecular tests.
DNA extraction
All strains (clinical and environment isolates) were subcultured on SDA plates and incubated at 29ºC for 24 -48 hours. Mycelia were collected in cryo-tubes containing 300 µL lysis buffer and 0.46 g glass beads and kept at 4ºC for 72 hours. The tube contents were homogenized using a SpeedMill PLUS Homogenizer (Analytikjena, Germany) for 6 minutes (3 cycles) and boiled at 100ºC for 20 minutes. 300 µL of sodium acetate (3 molar) was added to each tube and stored at -20ºC for 10 minutes. Supernatants were removed after a centrifugation at 12000 rpm for 10 minutes. DNA was purified using phenol-chloroformisoamyl alcohol according to a protocol devised by Makimura et al. [30] . Finally purified DNA was preserved at -20 ºC for further tests.
Molecular identification
β -Tubulin gene was used for the molecular detection of strains using primers pair, β t2a (forward), 5' GGTAACCAAATCGGTGCTGCTTTC 3' and β t2b (reverse) 5' ACCCTCAGTGTAGTGACCCTTGGC 3' [31] . PCR products subjected for sequence analysis and then sequences were manually verified by MEGA6 software package (https://www.megasoftware.net/) and aligned using the CLUSTALW algorithm. All sequences were compared to reference sequences in the GenBank (NCBI) and CBS database via the nucleotide BLAST ™ algorithm to obtain a definitive identification (similarity values ≥ 99%). Finally, all nucleotide sequences representative were deposited in the GenBank database. [33] [34] [35] [36] [37] [38] .
Antifungal susceptibility assay
Antifungals
MIC/MEC (µg/mL) Sensitive Resistance
Undefined Undefined MIC, Minimum inhibitory concentration; MEC, Minimum effective concentration
Statistical analysis
The Chi-squared test using the Social Science Statistics software (Online) was applied to determine the significant between variables and P value < 0.05 is considered as significance level. 37 clinical strains of black aspergilli were detected using molecular and sequencing techniques. Aspergillus niger (21, 56.8%) was the common strain followed by, A. tubingensis (11, 29 .8%), A. luchuensis (1, 2.7%), and black aspergilli (4, 10.8%) ( Table 2 ). Furthermore, out of 30 environmental black aspergilli isolates, 15 (50%) was identified as A. niger followed by, A. tubingensis (13, 43 .3%), A. piperis (1, 3.3%) and black aspergilli (1, 3.3%).
Results
Molecular detection of isolates
However, we could not identified four clinical and one environmental black aspergilli, using molecular technique due to inadequate DNA sample size. Our results showed that 32 (86.5%) of clinical strains were resistant to 2, 3 or 4 antifungals, 2 (5.4%) isolates were resistant to one antifungal and 3 (8.1%) were fully susceptible to antifungals ( Table 5 ). Two strains of A. tubingensis, one A. niger and one black aspergilli were resistant to all antifungals (except luliconazole). On the other hand, in environmental strains, 21 (70%) of strains were resistance to 2 -4 antifungals and only 30% of strains were resistance to one antifungals (Table 6 ). Two strains of A. niger and one A.
tubingensis were resistant to all antifungals (except luliconazole). There are the limited data in in vitro efficacy of antifungals against the black aspergilli both from clinical and environmental sources. While, the clinical and environmental strains had the same MIC ranges for caspofungin, the resistant to antifungal showed the clear differences between clinical and environmental strains (P = 0.048), where the clinical isolates showed higher resistant rate than the environmental strains. In a report by Badali et al., only 6.1% of environmental strains of A. niger were resistant to caspofungin and all clinical isolates ranged at 0.008-0.063 μ g/ml [21] . 
